Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001.
Publication
, Conference
Fleming, T; Borer, J; Lipicky, R; Armstrong, PW
Published in: Circulation
October 30, 2001
Duke Scholars
Published In
Circulation
DOI
EISSN
1524-4539
Publication Date
October 30, 2001
Volume
104
Issue
18
Start / End Page
E9039
Location
United States
Related Subject Headings
- Valsartan
- Valine
- United States Food and Drug Administration
- United States
- Tetrazoles
- Survival Rate
- Spironolactone
- Renal Insufficiency
- Receptor, Angiotensin, Type 1
- Randomized Controlled Trials as Topic
Citation
APA
Chicago
ICMJE
MLA
NLM
Fleming, T., Borer, J., Lipicky, R., & Armstrong, P. W. (2001). Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001. In Circulation (Vol. 104, p. E9039). United States. https://doi.org/10.1161/hc4301.101126
Fleming, T., J. Borer, R. Lipicky, and P. W. Armstrong. “Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001.” In Circulation, 104:E9039, 2001. https://doi.org/10.1161/hc4301.101126.
Fleming T, Borer J, Lipicky R, Armstrong PW. Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001. In: Circulation. 2001. p. E9039.
Fleming, T., et al. “Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001.” Circulation, vol. 104, no. 18, 2001, p. E9039. Pubmed, doi:10.1161/hc4301.101126.
Fleming T, Borer J, Lipicky R, Armstrong PW. Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001. Circulation. 2001. p. E9039.
Published In
Circulation
DOI
EISSN
1524-4539
Publication Date
October 30, 2001
Volume
104
Issue
18
Start / End Page
E9039
Location
United States
Related Subject Headings
- Valsartan
- Valine
- United States Food and Drug Administration
- United States
- Tetrazoles
- Survival Rate
- Spironolactone
- Renal Insufficiency
- Receptor, Angiotensin, Type 1
- Randomized Controlled Trials as Topic